PubRank

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Clinical Trial ID NCT01667536

PubWeight™ 3.77‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01667536

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Global cancer statistics. CA Cancer J Clin 2011 185.92
2 Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997 4.05
3 A simple method for the analysis of clustered binary data. Biometrics 1992 3.83
4 Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999 3.58
5 Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004 3.49
6 Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol 2011 2.22
7 The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008 2.19
8 Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009 2.03
9 Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007 1.95
10 In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000 1.91
11 Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996 1.88
12 Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998 1.61
13 A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009 1.60
14 Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995 1.43
15 PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 2013 1.33
16 Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006 1.23
17 Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998 1.01
18 Analysis of clustered matched-pair data for a non-inferiority study design. Stat Med 2003 0.97
19 Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA). EJNMMI Res 2014 0.91
20 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med 2013 0.90
21 Molecular and functional imaging for detection of lymph node metastases in prostate cancer. Int J Mol Sci 2013 0.78
Next 100